This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
The Department of Dermatology of the Beth Israel Hospital and Harvard Medical School (Boston) is asking dermatologists to enroll patients in a five-year study of the safety and efficacy of etretinate (Tegison, Roche Laboratories, Nutley, NJ) therapy for psoriasis. This study will document the incidence of important health events, including cardiovascular, eye, and hepatic disease, in patients who receive this therapy. To gather this information, trained interviewers will telephone patients once each year. Patients will be reimbursed $10 for their time each year they complete an interview.All patients with psoriasis who are treated with etretinate, either alone or in combination with other therapies (including methoxsalen plus ultraviolet light and ultraviolet light in the B range), who you anticipate will use etretinate at least one month per year are eligible. This study will not affect your care of your patient. One year after your patient enrolls, the
Stern RS. Announcement of Etretinate Follow-up Study. Arch Dermatol. 1987;123(4):423. doi:10.1001/archderm.1987.01660280023002